Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach.
Azevedo
L F
LF
Department of Biostatistics and Medical Informatics and CINTESIS, Centre for Research in Health Technologies and Information Systems, Faculty of Medicine, Oporto University, Portugal. lazevedo@med.up.pt
Magro
F
F
Portela
F
F
Lago
P
P
Deus
J
J
Cotter
J
J
Cremers
I
I
Vieira
A
A
Peixe
P
P
Caldeira
P
P
Lopes
H
H
Gonçalves
R
R
Reis
J
J
Cravo
M
M
Barros
L
L
Ministro
P
P
Lurdes
M
M
Duarte
A
A
Campos
M
M
Carvalho
L
L
Costa-Pereira
A
A
D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology*; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010349:Patient Compliance / Q000706:statistics & numerical data; D017891:Pharmacoepidemiology / Q000379:methods* / Q000706:statistics & numerical data; D011174:Portugal / Q000453:epidemiology; D015995:Prevalence; D012737:Sex Factors; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D019804:Mesalamine